Impact BioMedical Inc. (IBO) Stock

Impact BioMedical Inc. (IBO) is a Healthcare stock trading at $0.48 (as of 2026-08-21), with a market capitalization of $51.75M and a trailing P/E of 65.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Impact BioMedical Inc. develops specialty biopharmaceutical and consumer healthcare product candidates, including small-molecule polyphenol-based treatments under its Linebacker platform for oncology, inflammatory disorders, and neurology, as well as Laetose technology derived from sugar and inositol to address inflammatory and metabolic responses. It also works on functional fragrance formulations and Equivir/Equivir G polyphenol blends for potential antiviral use in health supplements and medications.

Understand Impact BioMedical Inc.: how it makes money

Impact BioMedical Inc. discovers and develops specialty biopharmaceutical and consumer healthcare products, using its Linebacker small-molecule platform (for oncology, inflammatory disorders, and neurology) and its Laetose technology (sugar plus inositol to inhibit inflammatory and metabolic response to sugar alone). It makes money by advancing and applying these developed treatment and product options.

The company’s profit path is tied to whether its discovery and development platforms, Linebacker and Laetose, can be translated into treatment options and consumer healthcare applications across oncology, inflammatory disorders, neurology, and related targets.

Business quality (Weak): The business description is clear about the company’s scientific platforms and intended application areas, but no segment revenue breakdown or operational KPIs were provided, limiting visibility into how performance is tracked.

Bull case

Platform breadth across disease areas: Linebacker is described as having applications in oncology, inflammatory disorders, and neurology, which gives the platform multiple potential target areas.
Differentiated technology framing: Laetose is described as being derived from a unique combination of sugar and inositol, designed to inhibit the inflammatory and metabolic response of sugar alone.

Bear case

Development risk before value is realized: The company engages in discovery and development, so there is inherent execution risk that platforms may not successfully become products or treatment options.
Limited reporting visibility in the provided dataset: No reportable segments, operating KPI labels, or segment-level revenue candidates were provided, which makes it harder to track drivers of performance.

Valuation — source: SEC EDGAR (first-party)
Price	$0.48
Market Cap	$51.75M
P/E Ratio	65.6
Price / Book	3.69
Price / Sales	1617.32

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$32000.00
Net Margin	-36993.8%
Revenue Growth (YoY)	-57.1%
EPS Growth (YoY)	-99.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	11.94 (safe)

Valuation vs Sector & Industry
Stock P/E	65.6
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	202.6%
vs Industry	286.8%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Insider Sells (12mo)	2
Top Institutional Holder	GEODE CAPITAL MANAGEMENT, LLC ($716246.00)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Frank D. Heuszel
Employees	2
Country	US
IPO Date	2024-09-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.